 |
| 03-Feb-10 | Initiated |
Brean Murray |
Buy |
$41 |
|
| 03-Dec-09 | Initiated |
Soleil |
Buy |
$35 |
|
| 10-Aug-09 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
|
|
| 05-Aug-09 | Downgrade |
Caris & Company |
Buy → Above Average |
$48 → $37 |
|
| 23-Jul-09 | Upgrade |
BMO Capital Markets |
Market Perform → Outperform |
|
|
| 23-Jul-09 | Reiterated |
Leerink Swann |
Mkt Perform |
$30 → $40 |
|
| 02-Jul-09 | Initiated |
Robert W. Baird |
Outperform |
$40 |
|
| 17-Jun-09 | Initiated |
Boenning & Scattergood |
Neutral |
|
|
| 28-May-09 | Initiated |
Morgan Joseph |
Buy |
$33 |
|
| 24-Feb-09 | Upgrade |
Boenning & Scattergood |
Neutral → Outperform |
$42 |
|
| 24-Feb-09 | Reiterated |
Canaccord Adams |
Buy |
$36 → $45 |
|
| 11-Dec-08 | Upgrade |
JP Morgan |
Neutral → Overweight |
|
|
| 30-Oct-08 | Upgrade |
Janney Mntgmy Scott |
Neutral → Buy |
|
|
| 25-Sep-08 | Initiated |
Caris & Company |
Above Average |
$48 |
|
| 20-Feb-08 | Reiterated |
BMO Capital Markets |
Market Perform |
$46 → $30 |
|
| 19-Feb-08 | Reiterated |
Lehman Brothers |
Overweight |
$60 → $47 |
|
| 19-Feb-08 | Reiterated |
Friedman Billings |
Mkt Perform |
$40 → $34 |
|
| 07-Nov-07 | Reiterated |
Lehman Brothers |
Overweight |
$54 → $60 |
|
| 07-Nov-07 | Reiterated |
HSBC Securities |
Overweight |
$44 → $61 |
|
| 07-Nov-07 | Reiterated |
BMO Capital Markets |
Market Perform |
$41 → $46 |
|
|
|
| 03-Feb-10 08:10AM | Coverage initiated on Onyx Pharma by Brean Murray Briefing.com |
| 02-Feb-10 04:00PM | Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference PR Newswire |
| 09:07AM | Onyx and FDA agree on cancer drug study design AP |
| 09:03AM | UPDATE - Onyx says FDA agrees on blood cancer drug trial design at Reuters |
| 08:04AM | InPlay: Onyx Pharma announces agreement with the FDA on a special protocol assessment for planned phase 3 carfilzomib combination trial in relapsed multiple myeloma Briefing.com |
| 08:00AM | Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma PR Newswire |
| 01-Feb-10 11:15AM | Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development PR Newswire |
| 29-Jan-10 04:02PM | Wake Up! You Still Have to Pay Attention at Motley Fool |
| 11:29AM | 5-Star Stocks Poised to Pop: Res-Care at Motley Fool |
| 27-Jan-10 09:48AM | 67% Decline In Consumable Cost For Human Genome Sequencing Seen In 2010 By First Analysis Equity Valuation Expert Wall Street Transcript |
| 22-Jan-10 03:19PM | Pfizer's Great Data Won't Do Much at Motley Fool |
| 19-Jan-10 08:05AM | Digging Deeper Into Adventrx Pharmaceuticals at TheStreet.com |
| 15-Jan-10 02:41PM | 3 Reasons to Sell Sequenom Today at Motley Fool |
| 13-Jan-10 04:18PM | 3 Stocks Springing Back at Motley Fool |
| 11-Jan-10 05:28PM | More Biotech Nuggets From the J.P. Morgan Confab: BioBuzz at TheStreet.com |
| 05-Jan-10 04:00PM | Onyx Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference PR Newswire |
| 08:30AM | Analysts Name Top Biotech Stocks for 2010: BioBuzz at TheStreet.com |
| 30-Dec-09 03:35PM | Pfizer Pflubs -- You Expected Otherwise? at Motley Fool |
| 18-Dec-09 02:34PM | 3 Reasons to Buy Dendreon Today at Motley Fool |
| 12:00PM | Celgene?s Surprising New Hope for Blood Cancer at Minyanville.com |
| 16-Dec-09 10:00AM | ONYX Pharmaceuticals, Inc. (ONXX) President and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell GlobeNewswire |
| 11-Dec-09 09:00PM | Nexavar may help breast cancer drugs work longer at Reuters |
| 04:45PM | Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies PR Newswire |
| 03:01PM | Remember The Alamo Embargo at CNBC |
| 10-Dec-09 04:00PM | Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program PR Newswire |
| 09-Dec-09 11:02AM | Positive Data from Onyx Zacks.com |
| 07-Dec-09 03:20PM | Biotechs to Watch in the Blood Business at Minyanville.com |
| 03:10PM | When the Big Guns Come In, You Get Blasted at Motley Fool |
| 01:07PM | UPDATE - Onyx drug shows promise in multiple myeloma study at Reuters |
| 08:01AM | Carfilzomib Data Demonstrate Promising Efficacy and Tolerability Signals in Ongoing Phase 1b/2 Combination Study with Lenalidomide and Low Dose Dexamethasone in Relapsed and/or Refractory Multiple Myeloma PR Newswire |
| 08:00AM | Onyx drug shows promise in multiple myeloma study at Reuters |
| 08:00AM | Carfilzomib Demonstrates Encouraging Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma in an Ongoing Phase 2 Study PR Newswire |
| 06-Dec-09 10:30AM | Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability PR Newswire |
| 04-Dec-09 06:39PM | Cramer's 'Mad Money' Recap: How to Play the Surprising Jobs Report (Update 1) at TheStreet.com |
| 06:21PM | The Coming Week's Game Plan: Blood, Tech and Jeers at CNBC |
| 04:00PM | Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference PR Newswire |
| 02-Dec-09 07:00AM | S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders PR Newswire |
| 25-Nov-09 04:00PM | Onyx Pharmaceuticals Announces December 2009 Investor Events PR Newswire |
| 20-Nov-09 12:26AM | [$$] U.K. Watchdog Says Bayer's Nexavar Is Too Expensive at The Wall Street Journal Online |
| 19-Nov-09 10:37PM | [$$] Corporate Watch at The Wall Street Journal Online |
| 04:01AM | UK health unit rejects Bayer drug as too expensive at MarketWatch |
| 16-Nov-09 02:05PM | Onyx wraps up $276M Proteolix buy at bizjournals.com |
| 09:44AM | ONYX PHARMACEUTICALS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements EDGAR Online |
| 09:29AM | Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc. PR Newswire |
| 12-Nov-09 06:50AM | Trading Outlook for ZymoGenetics Inc. Issued by StockPreacher.com GlobeNewswire |
| 11-Nov-09 04:00PM | Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference PR Newswire |
| 10:03AM | Healthcare Guru Adds Selected Biotech, Pharma Stakes Indie Research |
| 10-Nov-09 04:00PM | Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib and ONX 0803 at 51st American Society of Hematology Annual Meeting PR Newswire |
| 12:16PM | Blood Cancer Meeting Abstracts Released: BioBuzz at TheStreet.com |
| 09:20AM | Bristol Licenses Arthritis Drug: BioBuzz at TheStreet.com |
| 06:31AM | Celgene in the ASH Abstract Spotlight: BioBuzz at TheStreet.com |
| 06:31AM | Celgene in ASH Abstract Spotlight: BioBuzz at TheStreet.com |
| 09-Nov-09 01:55PM | Healthcare Bill Will Be Law By New Year Says Morningstar Strategist Wall Street Transcript |
| 07-Nov-09 09:04AM | ONYX PHARMACEUTICALS INC Financials EDGAR Online Financials |
| 06-Nov-09 07:58PM | Cramer's 8 Picks for Cancer's Cure at CNBC |
| 05-Nov-09 10:03PM | 2 Takeover Targets in the Pharma Market at CNBC |
| 06:50PM | [video] Battling Cancer with Biotech at CNBC |
| 12:17PM | Build Your Fortune With These Winners at Motley Fool |
| 04-Nov-09 04:00PM | Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference PR Newswire |
| 09:28AM | New Star Analyst Rankings for ONYX Pharmaceuticals, Inc. StarMine |
| 03-Nov-09 04:27PM | ONYX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online |
| 04:06PM | Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008 PR Newswire |
| 11:37AM | Affymax appoints board member as new chairman AP |
| 11:05AM | Affymax names Renton board chairman at bizjournals.com |
| 07:07AM | Q3 2009 Onyx Pharmaceuticals Earnings Release - Time Not Supplied CCBN |
| 29-Oct-09 08:00AM | Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting PR Newswire |
| 28-Oct-09 03:42PM | Saved by Emerging Markets. Sort Of. at Motley Fool |
| 27-Oct-09 04:00PM | Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast PR Newswire |
| 10:56AM | The Bull and Bear Story on GTx's Pending Drug Decision: BioBuzz at TheStreet.com |
| 10:56AM | The Bull and Bear Story on GTx's Pending Drug Approval: BioBuzz at TheStreet.com |
| 07:37AM | Big-Cap Biotech Worries Lead Sector Down: BioBuzz at TheStreet.com |
| 06:03AM | ONYX PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online |
| 23-Oct-09 03:34PM | Swine Flu Doesn't Need to Save Novartis at Motley Fool |
| 02:56PM | [$$] Two Top Ideas in Biotech at Barrons.com |
| 02:18PM | Not 50% Growth, but We'll Take It at Motley Fool |
| 02:30AM | Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer PR Newswire |
| 22-Oct-09 12:16PM | Onyx Pharmaceuticals: Could Acquiring Proteolix Be the Deal of the Year? at Seeking Alpha |
| 21-Oct-09 02:34PM | Here's Your Shot to Score Big at Motley Fool |
| 11:56AM | FDA Approval for GlaxoSmithKline Zacks.com |
| 20-Oct-09 05:25PM | Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst Wall Street Transcript |
| 08:24AM | New Formulation Of Diclofenac Successful In Two Phase III Trials, Approval Will Be Catalyst For Stock According To Industry Expert Wall Street Transcript |
| 14-Oct-09 06:50PM | Lightning Round OT: Onyx Pharma, NutriSystem and More at CNBC |
| 13-Oct-09 06:15AM | ONYX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exh EDGAR Online |
| 04:38AM | Weekly Street Sentiment: Sell Side Loves Everything and Everybody at Seeking Alpha |
| 12-Oct-09 06:45PM | [video] Dow Nears 10,000 at Forbes.com +5.06% |
| 05:59PM | Onyx Pharma will pay up to $851M for Proteolix AP |
| 05:56PM | Business Highlights AP |
| 05:32PM | [$$] Corporate Watch at The Wall Street Journal Online |
| 05:14PM | [$$] Stocks in the Spotlight Monday at Barrons.com |
| 05:11PM | Dow Can't Close 10,000 Deal at TheStreet.com |
| 04:44PM | KB Home, AMD, Black & Decker big movers AP |
| 04:09PM | Onyx Strikes Gold at Motley Fool |
| 03:51PM | [$$] Onyx Pharmaceuticals Agrees to Buy Proteolix at The Wall Street Journal Online |
| 03:45PM | Dow Gives Back Gains at TheStreet.com |
| 03:05PM | Onyx Pharmaceuticals to buy Proteolix at bizjournals.com |
| 02:37PM | Deal Profile: Onyx Pharmaceuticals to Buy Proteolix at The Wall Street Journal Online |
| 01:10PM | Energy stocks lead Wall Street rally at FT.com |
| 12:55PM | Biotech Stocks: Drug stocks climb; DepoMed sinks at MarketWatch |
| 12:46PM | Spectrum Feeling Ill Effects of FDA Rejection: BioBuzz at TheStreet.com |
| 12:39PM | Stocks Rise on Earnings Optimism at TheStreet.com |
|
|
| Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies targeting the molecular mechanisms causing cancer in the United States and internationally. Its lead product includes Nexavar (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. This product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals. The company is also conducting various ongoing trials on Nexavar for conditions, such as non-small cell lung cancer, melanoma, breast cancer, and other cancers. It also develops ONX 0801, an oncology compound in preclinical development stage, under a development and license agreement with BTG International Limited. In addition, Onyx Pharmaceuticals, through a development collaboration, option, and license agreement with S*BIO Pte Ltd, owns options to license the rights of ONX 0803 and ONX 0805. ONX 0803 is an orally available, potent, and selective inhibitor of JAK2; and ONX 0805 is a JAK2 inhibitor. Further, the company has a research and development collaboration agreement with Warner-Lambert Company to discover and commercialize small molecule drugs that restore the control of, or otherwise intervene in, the misregulated cell cycle in tumor cells. Onyx Pharmaceuticals was founded in 1992 and is headquartered in Emeryville, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Batlin Judy A | VP, Org Learning, Dvlpmnt & HR | Jan 19 | Sale | 29.96 | 738 | 22,110 | 12,261 | Jan 20 05:26 PM | | Brege Laura | EVP and Chief Business Officer | Jan 15 | Option Exercise | 15.44 | 12,500 | 193,000 | 30,293 | Jan 20 05:23 PM | | Brege Laura | EVP and Chief Business Officer | Jan 15 | Sale | 30.12 | 12,500 | 376,500 | 17,793 | Jan 20 05:23 PM | | Fust Matthew K | Chief Financial Officer | Jan 06 | Sale | 29.60 | 1,919 | 56,802 | 11,581 | Jan 07 07:06 PM | | Brege Laura | EVP and Chief Business Officer | Dec 02 | Option Exercise | 15.44 | 12,500 | 193,000 | 30,016 | Dec 04 12:32 PM | | Brege Laura | EVP and Chief Business Officer | Dec 02 | Sale | 30.00 | 12,500 | 375,000 | 17,516 | Dec 04 12:32 PM | | Lasowski Juergen | SVP, Corporate Development | Aug 14 | Sale | 30.73 | 3,182 | 97,783 | 9,200 | Aug 14 06:51 PM | | Brege Laura | EVP and Chief Business Officer | Jul 22 | Option Exercise | 15.44 | 25,000 | 386,000 | 42,516 | Jul 24 01:46 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jul 22 | Option Exercise | 25.30 | 9,747 | 246,599 | 20,597 | Jul 24 01:48 PM | | Lasowski Juergen | SVP, Corporate Development | Jul 22 | Sale | 35.98 | 8,828 | 317,642 | 12,382 | Jul 24 01:50 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jul 22 | Sale | 35.90 | 11,848 | 425,343 | 8,749 | Jul 24 01:48 PM | | Brege Laura | EVP and Chief Business Officer | Jul 22 | Sale | 35.90 | 25,000 | 897,500 | 17,516 | Jul 24 01:46 PM | | Lasowski Juergen | SVP, Corporate Development | Jun 26 | Sale | 26.27 | 3,332 | 87,533 | 21,210 | Jun 29 06:46 PM | | Lasowski Juergen | SVP, Corporate Development | May 20 | Sale | 23.75 | 1,440 | 34,200 | 24,542 | May 21 04:48 PM | | COLES N ANTHONY | President & CEO | Apr 06 | Sale | 27.31 | 7,500 | 204,825 | 81,391 | Apr 08 03:54 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Apr 01 | Sale | 27.89 | 1,233 | 34,392 | 10,850 | Apr 02 08:14 PM | | Brege Laura | EVP and Chief Business Officer | Apr 01 | Sale | 27.90 | 5,333 | 148,791 | 17,241 | Apr 02 07:57 PM | | COLES N ANTHONY | President & CEO | Apr 01 | Sale | 27.89 | 6,109 | 170,402 | 68,891 | Apr 02 07:47 PM | | Batlin Judy A | VP, Org Learning, Dvlpmnt & HR | Feb 09 | Sale | 33.53 | 2,834 | 95,024 | 8,999 | Feb 10 02:15 PM | | Batlin Judy A | VP, Org Learning, Dvlpmnt & HR | Jan 21 | Sale | 33.15 | 1,667 | 55,261 | 11,833 | Jan 23 02:45 PM | | Brege Laura | EVP and Chief Business Officer | Jan 15 | Option Exercise | 15.44 | 12,500 | 193,000 | 28,074 | Jan 20 04:45 PM | | Brege Laura | EVP and Chief Business Officer | Jan 15 | Sale | 32.81 | 12,500 | 410,125 | 15,574 | Jan 20 04:45 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jan 06 | Option Exercise | 25.30 | 8,982 | 227,245 | 17,315 | Jan 06 04:55 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jan 06 | Sale | 35.00 | 8,982 | 314,370 | 8,333 | Jan 06 04:55 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jan 05 | Option Exercise | 25.30 | 771 | 19,506 | 9,104 | Jan 06 04:55 PM | | WOOD JULIANNA R | VP, Corp. Communication/I.R. | Jan 05 | Sale | 35.00 | 771 | 26,985 | 8,333 | Jan 06 04:55 PM |
|
|
|
|
|
|
